Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients
Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in Non-hodgkin Lymphoma Patients
Sponsor: Peking Union Medical College Hospital
This observational or N/A phase trial investigates Diffuse Large B Cell Lymphoma and Peripheral T Cell Lymphoma and is currently ongoing. Peking Union Medical College Hospital leads this study, which shows 13 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
▶ Show 8 earlier versions
-
Feb 2020 — Nov 2020 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Aug 2018 — Feb 2020 [monthly]
Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
May 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Peking Union Medical College Hospital
For direct contact, visit the study record on ClinicalTrials.gov .